We are monitoring the impact of COVID-19 on Diabetic Retinopathy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 875
Share on
Share on

Global Diabetic Retinopathy Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Type, Indication, End User and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 875
Pages: 178

Diabetic Retinopathy Market Size (2021 to 2026)

As per our report, the global diabetic retinopathy market size was valued at USD 7.45 billion in 2021 and estimated to reach USD 10.4 billion by 2026, showcasing a CAGR of 6.9% from 2021 to 2026. High target disease dominance, product launches by the leading diabetic retinopathy market players, increasing strategic developments such as partnerships and agreements, and favorable research funding scenarios are the key market growth drivers.

It is a medical complication that affects the retina in the eye in diabetic patients. It impacts the blood vessels in the eye, which may lead to vision loss and blindness. Patients have to undergo an eye examination test like Visual acuity test, Pupil dilation, Ophthalmoscopy or fundus photography, Fundus Fluorescein angiography (FFA), Retinal vessel analysis, or Optical coherence tomography (OCT) to confirm the disease. As per the National Center for Biotechnology Information, the populace affected with Diabetic Retinopathy (DR) was 126 million in 2010. This value to reach 191 million by the end of 2030, which is to influence the growth of the diabetic retinopathy market at an equal pace.

MARKET DRIVERS:

Rising incidences of diabetes, inability to cope with the retinal screening of patients with diabetes and growth in the awareness among people over the diagnosis and treatment services in the hospitals are primarily expanding the global diabetic retinopathy market. Diabetic Retinopathy affects over 33% of diabetes patients and is the principal cause of blindness in the 20-79 aged population with diabetes. India, China, and Bangladesh alone are representing over 40% of the global diabetic retinopathy burden. In Africa, two-thirds of people with diabetes remain undiagnosed. About 30% of people with Diabetic Retinopathy present the greatest unmet need. In the United States, Diabetic Retinopathy is the leading cause of new cases of legal blindness among adults aged 20 to 79 years.

Additionally, increasing demand for continuous monitoring of the diseases, rising capital income in developed and developing countries, and growing elderly people populations further fuel market growth. Rising demand for cost-effective and protective treatment procedures and having the least quality diagnosis are estimated to favor the global diabetic retinopathy market growth.

MARKET RESTRAINTS:

Less knowledge about the treatment options, shortage of skilled ophthalmologists, and strict government rules are major restraints to the market growth.

Diabetic Retinopathy is a common diabetic eye disease; leads to eye blindness for diabetic patients. The lack of trained professionals or technically skilled professionals is the major restraints of the diabetic retinopathy market. Further, the major drawback of the diabetic retinopathy market was the costliest treatment. The availability of advanced technology and various treatment methods like laser treatment is hindering the market. Moreover, prescribing the medication for decreasing the impact of diabetic retinopathy will be a significant drawback for the market. The lengthy approval times for drugs and lack of awareness about diabetic retinopathy treatment in emerging countries like India, South Africa, etc., will affect the market growth.

Impact of COVID-19 on the global diabetic retinopathy market:

The World Health Organisation had declared the coronavirus as a pandemic. More than 200 countries declared a lockdown to stop the spread of novel coronavirus. Moreover, 110 million were affected with COVID 19, 61.9 million people were recovered, and more than 2.43 million people died. 

The pandemic has affected so many industries or markets differently. The healthcare sector has both positive and negative impacts due to novel coronavirus diseases.  Due to lockdown, all manufacturing industries, companies, and others were shut, where the supply chain got disturbed. The patients are unable to get their medicines due to a lack of supply. Moreover, due to lack of workers and strict lockdown restrictions, there is a decline in productivity; thus, there is no supply for the demand. However, the market's key players try their best to overcome the pandemic by releasing new technologies into the market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Analysed

By Treatment Type, Indication, End User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global diabetic retinopathy market has been segmented and sub-segmented based on the treatment type, indication, end-user, and region.

Diabetic Retinopathy Market - By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

Based on the treatment type, the Anti-Vascular Endothelial Growth Factor (VEGF) segment leads with the highest shares of the market, followed by the laser treatment segment. The laser treatment is further divided into focal laser treatment and scatter laser treatment. Focal laser treatment is growing tremendously with the rise in the prevalence of early diagnosis. The availability of skilled physicians in managing health disorders is significantly influencing the growth of the market. Also, increasing support from the government through investments is leveraging the growth of the market.

Diabetic Retinopathy Market - By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

Based on indication, the Non-proliferative diabetic retinopathy segment is holding dominant shares of the market. On-going research in the development of innovative procedures for diagnosing various diseases is elevating the market's growth. Increasing the scale of specialty care centers is impacting positively on the growth of the market.

Diabetic Retinopathy Market - By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Based on end-user, the Hospitals and clinics end-user segments are having the highest shares of the market. A rise in the construction activities of hospitals with the latest equipment is primarily boosting up the growth rate of the market. If the diabetes is untreated properly, it may damage blood vessels in the retina of an eye, which is leveling up the market demand. Increasing expenditure on healthcare is magnifying the growth of the diabetic retinopathy market.

Diabetic Retinopathy Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, North American remains the central revenue-generating region; this is happening due to the high obesity rates in this region. 

Europe has a large population of baby boomers. This factor helps Europe stand 2nd position in leading the highest shares in the diabetic retinopathy market.

The Asia-Pacific region to grow at the highest CAGR. The growing population of diabetes and the local people's changing lifestyles are primary factors boosting the market in the Asia Pacific. 

The profitable growth of the Asia-Pacific diabetic retinopathy market is due to many people with diabetes in this region. Emerging economies such as Japan and China in the Asia-Pacific region will grow significantly during the forecast period due to rising disposable income, growing elderly population, increased funding for diabetes research, and innovation in diagnostics. The Chinese market increases at a healthy rate, whereas Japan is the largest market in the Asia-Pacific region due to high medical expenses and increasing disposable income. Besides, increased use of Lucent to drive APAC Diabetic Retinopathy Market growth in the area.

KEY MARKET PARTICIPANTS:

Some of the notable companies dominating the global diabetic retinopathy market profiled in this report are Bayer Healthcare, Pfizer, Inc., Hoffmann-La Roche Ltd, Regeneron Pharmaceutical, Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science, Inc., and Ampio Pharmaceuticals Inc.       

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Type of Treatment                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                          

                                5.1.2 Intraocular Steroid Injection                           

                                5.1.3 Laser Surgery                         

                                5.1.4 Vitrectomy                             

                5.2 By Indication                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                      

                                                5.2.1.1 Mild       

                                                5.2.1.2 Moderate            

                                                5.2.1.3 Severe  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                    

                5.3 By End Users                                             

                                5.3.1 Hospitals                  

                                5.3.2 Ophthalmic Clinics                               

                                5.3.3 Ambulatory Surgical Centers                           

6. Geographical Analysis                                                              

                6.1 North America                                          

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.2 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                           

                                6.2.6 France                      

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                        

                                6.3.5 South Korea                           

                                6.3.6 Australia                  

                6.4 Latin America                                            

                                6.4.1 Introduction                           

                                6.4.2 Brazil                         

                                6.4.3 Mexico                     

                                6.4.4 Argentina                

                                6.4.5 Rest of Latin America                         

                6.5 Middle East & Africa                               

                                6.5.1 Introduction                           

                                6.5.2 Middle-East                            

                                6.5.3 Africa                        

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Bayer AG                                     

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Hoffmann-La Roche ltd                                          

                8.4 Regeneron Pharmaceutical Inc.                                         

                8.5 Novartis AG                                

                8.6 Valeant Pharmaceutical International Inc.                                     

                8.7 Abbott Laboratories Inc.                                       

                8.8 Alimera Science Inc.                                                

                8.9 Ampio Pharmaceuticals Inc.                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  3. Global Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  8. Global Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  10. Global Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  15. Global Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  16. Global Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  20. North America Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  25. North America Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  27. North America Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  30. North America Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  32. North America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  34. North America Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  35. United States Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  36. United States Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  37. United States Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  38. United States Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  39. Canada Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  40. Canada Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  41. Canada Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  42. Canada Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  43. Europe Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  44. Europe Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  45. Europe Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  46. Europe Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  47. Europe Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  48. Europe Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  49. Europe Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  50. Europe Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  51. Europe Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  52. Europe Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  53. Europe Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  54. Europe Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  55. Europe Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  56. Europe Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  57. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  58. Europe Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  59. Europe Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  60. U.K Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  61. U.K Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  62. U.K Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  63. U.K Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  64. Spain Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  65. Spain Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  66. Spain Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  67. Spain Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  68. Germany Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  69. Germany Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  70. Germany Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  71. Germany Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  72. Italy Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  73. Italy Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  74. Italy Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  75. Italy Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  76. France Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  77. France Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  78. France Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  79. France Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  80. Asia-Pacific Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  81. Asia-Pacific Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  82. Asia-Pacific Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  83. Asia-Pacific Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  84. Asia-Pacific Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  85. Asia-Pacific Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  86. Asia-Pacific Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  87. Asia-Pacific Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  88. Asia-Pacific Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  89. Asia-Pacific Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  90. Asia-Pacific Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  91. Asia-Pacific Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  92. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  93. Asia-Pacific Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  94. Asia-Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  95. Asia-Pacific Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  96. Asia-Pacific Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  97. China Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  98. China Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  99. China Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  100. China Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  101. India Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  102. India Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  103. India Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  104. India Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  105. Japan Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  106. Japan Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  107. Japan Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  108. Japan Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  109. South Korea Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  110. South Korea Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  111. South Korea Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  112. South Korea Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  113. Australia Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  114. Australia Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  115. Australia Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  116. Australia Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  117. Latin America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  118. Latin America Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  119. Latin America Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  120. Latin America Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  121. Latin America Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  122. Latin America Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  123. Latin America Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  124. Latin America Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  125. Latin America Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  126. Latin America Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  127. Latin America Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  128. Latin America Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  129. Latin America Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  130. Latin America Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  131. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  132. Latin America Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  133. Latin America Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  134. Brazil Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  135. Brazil Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  136. Brazil Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  137. Brazil Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  138. Argentina Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  139. Argentina Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  140. Argentina Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  141. Argentina Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  142. Mexico Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  143. Mexico Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  144. Mexico Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  145. Mexico Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  146. Middle East & Africa Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  147. Middle East & Africa Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  148. Middle East & Africa Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  149. Middle East & Africa Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  150. Middle East & Africa Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  151. Middle East & Africa Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  152. Middle East & Africa Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  153. Middle East & Africa Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  154. Middle East & Africa Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  155. Middle East & Africa Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  156. Middle East & Africa Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  157. Middle East & Africa Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  158. Middle East & Africa Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  159. Middle East & Africa Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  160. Middle East & Africa Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  161. Middle East & Africa Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  162. Middle East & Africa Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  163. Middle East Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  164. Middle East Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  165. Middle East Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  166. Middle East Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  167. Africa Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  168. Africa Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  169. Africa Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  170. Africa Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample